Journal of Clinical Oncology 2017

42 papers
The 2017 edition of the Journal of Clinical Oncology featured research on immunotherapy, diagnostic methodologies, and supportive care. Investigations into immune checkpoint inhibitors were prominent, featuring trials of avelumab for nasopharyngeal carcinoma and the integration of checkpoint inhibition with radiation for pancreatic cancer. Research also explored cellular therapies, specifically CD133-redirected CAR T-cell treatments for advanced malignancies. Urologic oncology was a recurring theme, with studies evaluating prostate cancer detection rates through fusion versus systematic biopsies. Prolific authors such as Peter A. Pinto, Barış Türkbey, and Peter L. Choyke contributed to this area. Beyond clinical interventions, the year’s publications addressed the intersection of socioeconomic status and hospital performance, as well as the importance of managing depression in patients with advanced cancer. Diagnostic research included the study of metabolomics signatures in serum as potential early indicators of thoracic cancer. These works reflect a focus on refining both therapeutic applications and the systemic factors affecting patient outcomes.

Top Research Directions

The 6 research directions with Journal of Clinical Oncology 2017 papers, ranked by paper count, next to 2016. Share is the fraction of the edition’s papers in the direction.

#Direction20172016Share 2017Share 20162016 rank
1Analysis of Covariance for Controlled Group Comparisons102.4%0.0%—
2Comparative Intervention Designs for Causal Inference102.4%0.0%—
3Evaluating Clinical Outcomes Using Historical Patient Cohorts102.4%0.0%—
4Institutional Practice Variation and Clinical Generalizability102.4%0.0%—
5Open-Label Bias in Clinical Trials102.4%0.0%—
6Stratified Subgroup Analysis for Identifying Effect Heterogeneity112.4%2.8%13

Download all directions as CSV

Institutions

Institutions credited by Journal of Clinical Oncology 2017 papers: a paper credits every institution named in its affiliations, once. 2 institutions share 2 credited papers.

#InstitutionPapersShare20162016 rank
1Massachusetts General Hospital 2100.0%0—
2Harvard University 150.0%0—

Download all institutions as CSV

About this data

Papers. Journal of Clinical Oncology 2017 lists 42 papers on Lacuna, duplicate versions counted once; rejected and withdrawn submissions are left out.

Directions. Directions are Lacuna’s clustering of the concept elements extracted from each paper, so a paper can belong to several and direction counts add up to more than the paper count. A direction’s share is its papers divided by the edition’s papers. Comparisons with 2016 use shares, since the edition went from 36 to 42 papers.

Institutions. A paper credits each institution named in its affiliations, resolved to a ROR record, once. 2 of 42 papers (4.8%) credit at least one institution and are the base for institution shares; the rest have no resolved affiliation yet.

Data. Counts come from Lacuna’s data build of 2026-11-20 and change as papers are added. Tables as CSV: directions · institutions. Cite as: Lacuna, “Journal of Clinical Oncology 2017”, https://lacuna.tiptreesystems.com/venue/journal-of-clinical-oncology/2017.

Top Authors

AuthorPapers
Bradford J Wood7
Christopher Li Hsian Chen2
Jorge J. Nieva2
Jianhua Chen1
Jing Wang1
Junmo Kim1
Xiaofei Wang1
Yuming Jiang1

Papers

Title
ACRIN 6698 trial: Quantitative diffusion-weighted MRI to predict pathologic response in neoadjuvant chemotherapy treatment of breast cancer.
Alcohol consumption adjusted by aldehyde dehydrogenase 2 genotype: A potential risk factor for gastric cancer?
A model for predicting focal ablation candidates in patients with prostate cancer based on MRI and biopsy criteria.
An open-label, single-arm, multi-institutional phase II trial of avelumab for recurrent, metastatic nasopharyngeal carcinoma.
An oral methionine aminopeptidase II inhibitor for high-risk non-muscle invasive bladder cancer relapsed after intravesical therapies: Update of a phase II trial.
A pilot study of immune checkpoint inhibition in combination with radiation therapy in patients with metastatic pancreatic cancer.
Association of body mass index (BMI) and stage in patients with non-small cell lung cancer harboring KRAS mutations.
Beyond classical risk adjustment: Socioeconomic status and hospital performance in urologic oncology.
Can index lesion tumor volume on T2 weighted MRI predict biochemical recurrence following radical prostatectomy?
c-Cbl expression as a novel predictive marker of survival in patients with metastatic colorectal cancer.
CD133-redirected chimeric antigen receptor engineered autologous T-cell treatment in patients with advanced and metastatic malignancies.
Changes in prostate cancer detection rate of fusion versus systematic biopsy over time: A single center experience.
Clinical observation of yizhongshengxue capsule on the treatment of advanced gastric cancer-related anemia.
CLOVIZ: Clinical outcomes visualization of IMDC criteria in metastatic renal cell carcinoma for patient-centered decision making.
Comparing mortality of colorectal cancer and gastrointestinal bleeding among patients with long-term use of low dose aspirin: A population-based study of 689,209 patients.
Comparison of multiparametric MRI to PSA kinetics as an indication of prostate cancer progression in men on active surveillance.
Defining the elements of early palliative care (PC) that are associated with patient-reported outcomes (PROs) and the delivery of end-of-life (EOL) care.
Effects of Early Integrated Palliative Care in Patients With Lung and GI Cancer: A Randomized Clinical Trial
Focal therapy for prostate cancer: Attitude and practice patterns.
Gefitinib as third-line re-challenge treatment in advanced NSCLC patients with EGFR activating mutation who benefited from first-line gefitinib treatment followed by second-line chemotherapy.
Hematology and oncology patient perceptions of inpatient care coordination at an urban academic teaching center.
Index lesion tumor volume on MRI to predict adverse pathologic outcomes following radical prostatectomy.
Interim FDG-PET imaging during neoadjuvant chemoradiotherapy for esophageal cancer: Correlation with pathologic response.
Intermediate-term outcomes from the DISSRM registry: A prospective analysis of active surveillance in patients with small renal masses.
Investigating novel resistance mechanisms to third generation EGFR TKI osimertinib in non-small cell lung cancer patients using next generation sequencing.
Metabolomics signature in serum months to years before thoracic cancer: The HUNT study.
Multimodal therapy for cancer related fatigue in patients with prostate cancer receiving radiotherapy and androgen deprivation therapy.
Outpatient hematologist and oncologist perceptions of inpatient continuity visits at an urban academic medical center.
Patient engagement with a smartphone mobile app for adherence to oral chemotherapy.
Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non–Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801
Post-discharge transitions of care for hospitalized patients with advanced cancer.
Prognostic and predictive value of immunoscore signature in gastric cancer.
Randomized trial of a smartphone mobile app for adherence to oral chemotherapy.
Role of Patient Coping Strategies in Understanding the Effects of Early Palliative Care on Quality of Life and Mood
Serum phosphatidylcholine is lower among breast cancer patients on systemic chemotherapy.
Suitability factors of core needle biopsies for pharmacodynamic (PD) studies.
Superior prognosis prediction performance of deep learning for gastric cancer compared to Yonsei prognosis prediction model using Cox regression.
The importance of recognizing and addressing depression in patients with advanced cancer.
Thermal ablation for treatment of hepatic metastasis from thymic epithelial tumors (TETs).
Training and skills assessment for MRI/TRUS fusion-guided prostate biopsy: End-fire vs. side-fire ultrasound probes.
Tremelimumab: A monoclonal antibody against CTLA-4—In combination with radiofrequency ablation (RFA) in patients with biliary tract carcinoma (BTC).
Use of liquid biopsy for detection of renal cell carcinoma.